Related Experiment Video
Updated: Jun 28, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to
Madeleine S Q Kortenhorst1, Marianna Zahurak, Shabana Shabbeer
1Prostate Cancer Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA.
Purpose:
Although microarray technology has been widely adopted by the scientific community, analysis of the ensuing data remains challenging. In this article, we present our experience with a complex design microarray experiment on resistance mechanisms of histone deacetylase inhibitors (HDACI).
Experimental Design:
To improve our understanding of the underlying mechanism of HDACI resistance in prostate cancer cells, we designed a novel "multiple-loop, double-cube" cDNA microarray experiment. In the experiment of 22 arrays, DU145 and PC3 cells were treated with two different HDACIs (vorinostat and valproic acid) and incubation periods (48 and 96 h). Preprocessing included exploratory analyses of the quality of the arrays and intensity-dependent within-array Loess normalization. An ANOVA model was used for inference. The results were validated by Western blot analysis of known treatment targets.
Results:
Treatment of PC3 and DU145 cells with HDACIs caused 2.8% to 10% (P<0.001) differential expression across conditions; 51% to 73% of these genes were up-regulated and 28% to 49% were down-regulated. The extent of differential expression was associated with cell line (DU145>PC3), HDACI (valproic acid >or= vorinostat), and duration of treatment (96>48 h). We identified known and new treatment targets involved in cell cycle and apoptosis.
Conclusion:
A multiple-loop, double-cube microarray design can be used to identify HDACI-induced changes in gene expression possibly related to drug resistance.
Insights
This study used a novel microarray design to identify gene expression changes related to histone deacetylase inhibitor resistance in prostate cancer cells. The findings reveal key genes involved in cell cycle and apoptosis that may drive drug resistance.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Histone deacetylase inhibitors (HDACIs) are a promising class of drugs for cancer treatment.
- Understanding mechanisms of HDACI resistance is crucial for improving therapeutic efficacy.
- Microarray technology offers a powerful tool for analyzing gene expression patterns.
Purpose of the Study:
- To investigate the gene expression profiles associated with HDACI resistance in prostate cancer cells.
- To evaluate a novel "multiple-loop, double-cube" cDNA microarray experimental design for complex biological studies.
- To identify potential therapeutic targets and resistance mechanisms.
Main Methods:
- A "multiple-loop, double-cube" cDNA microarray experiment was conducted using DU145 and PC3 prostate cancer cell lines.
- Cells were treated with two HDACIs (vorinostat, valproic acid) for two durations (48, 96 hours).
- Data preprocessing involved Loess normalization, and statistical inference was performed using an ANOVA model. Western blot analysis validated key findings.
Main Results:
- HDACI treatment induced significant differential gene expression (2.8%–10%, P<0.001) in prostate cancer cells.
- Gene expression changes varied by cell line, HDACI type, and treatment duration.
- Identified genes implicated in cell cycle regulation and apoptosis, offering insights into resistance mechanisms.
Conclusions:
- The "multiple-loop, double-cube" microarray design is effective for identifying HDACI-induced gene expression changes.
- This approach can reveal molecular mechanisms underlying drug resistance in cancer.
- Findings contribute to the development of strategies to overcome HDACI resistance.
